Table 3.

SCFE follow-up studies evaluating CAM deformity, osteoarthritis, and patient-reported outcome

A	B	C	D	E	F	G	H
Zilkens et al.	12 (7–17)	11 (4–20)	47	30 of 38 a	35 of 38 b	SF-36 PF 86.7 SF-37 RP 78.9	HHS 92, range 60–100
Fraitzl et al.	14 (12–17)	14 (11–21)	16	13 of 16a	c c	c	c
Miese et al.	13 (9–15)	12 (4–39)	35	29 of 35 a	19 of 175 d 44 of 175 d	c	c
Wensaas et al. 2012		37 (21–50)	43	c a	10 of 43	c	HHS 92, range 53–100
Wensaas et al. 2011	13 (11–15)	38 (21–57)	76	c a	23 of 76	EQ-5D Index 0.84 EQ-5D Visual 74	HHS 88, range 45–100
The current study	12 (10–14)	15 (10–17)	24	15 of 24 14 of 17	1 of 24 11 of 14	SF-36 PCS 54 SF-36 MCS 56	Median WOMAC 100, range 73–100

^a No MRI performed.

^b No differentiation between osteoarthritis and pre-osteoarthritis.

^c Not evaluated.

^d Measured at 5 places in each hip

A Study

B Age at surgery (range)

C Mean follow-up (range), year

D No. SCFE hips

E No. of patients with Cam deformity after SCFE radiography / MRI

F No. of patients with osteoarthritis/pre-osteoarthritis

GPatient-reported outcome (HRQoL) after SCFE

HPatient-reported joint function outcome after SCFE, HHS Harris Hip Score